{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:17:05Z","timestamp":1792783025541,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Rijksinstituut voor Ziekte- en Invaliditeitsverzekering Belgium","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"https:\/\/ror.org\/02p1wzv32","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00262-020-02618-4","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T10:44:15Z","timestamp":1593168255000},"page":"2589-2598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9841","authenticated-orcid":false,"given":"Yanina","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Corthals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Schats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter-Jan","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teofila","family":"Seremet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Heirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Brochez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kockx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Thielemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"issue":"8","key":"2618_CR1","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al (2017) IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127(8):2930\u20132940. https:\/\/doi.org\/10.1172\/JCI91190","journal-title":"J Clin Invest"},{"key":"2618_CR2","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","volume":"28","author":"CM Balch","year":"2010","unstructured":"Balch CM, Gershenwald JE, Soong S et al (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452\u20132459. https:\/\/doi.org\/10.1200\/JCO.2009.27.1627","journal-title":"J Clin Oncol"},{"key":"2618_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1057673","volume":"5","author":"KF Bol","year":"2016","unstructured":"Bol KF, Aarntzen EHJG, in\u2019t Hout FEM et al (2016) Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology 5:1\u20138. https:\/\/doi.org\/10.1080\/2162402X.2015.1057673","journal-title":"Oncoimmunology"},{"key":"2618_CR4","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/mt.2008.77","volume":"16","author":"A Bonehill","year":"2008","unstructured":"Bonehill A, Tuyaerts S, Van Nuffel AMT et al (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16:1170\u20131180. https:\/\/doi.org\/10.1038\/mt.2008.77","journal-title":"Mol Ther"},{"key":"2618_CR5","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1158\/1078-0432.CCR-08-2982","volume":"15","author":"A Bonehill","year":"2009","unstructured":"Bonehill A, Van Nuffel AMT, Corthals J et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15:3366\u20133375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2982","journal-title":"Clin Cancer Res"},{"key":"2618_CR6","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/jco.2009.23.4799","volume":"27","author":"DR Byrd","year":"2009","unstructured":"Byrd DR, Sondak VK, Soong S et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199\u20136206. https:\/\/doi.org\/10.1200\/jco.2009.23.4799","journal-title":"J Clin Oncol"},{"key":"2618_CR7","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.4049\/jimmunol.180.5.3585","volume":"180","author":"J Carrasco","year":"2014","unstructured":"Carrasco J, Van Pel A, Neyns B et al (2014) Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 180:3585\u20133593. https:\/\/doi.org\/10.4049\/jimmunol.180.5.3585","journal-title":"J Immunol"},{"key":"2618_CR8","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud AI, Wolchok JD, Robert C et al (2016) Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 34:4102\u20134109. https:\/\/doi.org\/10.1200\/JCO.2016.67.2477","journal-title":"J Clin Oncol"},{"key":"2618_CR9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378:1789\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa1802357","journal-title":"N Engl J Med"},{"key":"2618_CR10","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375:1845\u20131855. https:\/\/doi.org\/10.1056\/NEJMoa1611299","journal-title":"N Engl J Med"},{"key":"2618_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/nejmoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813\u20131823. https:\/\/doi.org\/10.1056\/nejmoa1708539","journal-title":"N Engl J Med"},{"key":"2618_CR12","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1007\/s12032-012-0168-1","volume":"29","author":"S Markowicz","year":"2012","unstructured":"Markowicz S, Nowecki ZI, Rutkowski P et al (2012) Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. Med Oncol 29:2966\u20132977. https:\/\/doi.org\/10.1007\/s12032-012-0168-1","journal-title":"Med Oncol"},{"key":"2618_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd008955.pub2","author":"S Mocellin","year":"2013","unstructured":"Mocellin S, Lens MB, Pasquali S et al (2013) Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd008955.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2618_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(06)70938-X","volume":"7","author":"DW Ollila","year":"2006","unstructured":"Ollila DW (2006) Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol 7:919\u2013924. https:\/\/doi.org\/10.1016\/S1470-2045(06)70938-X","journal-title":"Lancet Oncol"},{"key":"2618_CR15","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.2009.26.2063","volume":"28","author":"E Romano","year":"2010","unstructured":"Romano E, Scordo M, Dusza SW et al (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28:3042\u20133047. https:\/\/doi.org\/10.1200\/JCO.2009.26.2063","journal-title":"J Clin Oncol"},{"key":"2618_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/mt.2012.11","volume":"20","author":"AMT Van Nuffel","year":"2012","unstructured":"Van Nuffel AMT, Benteyn D, Wilgenhof S et al (2012) Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4\u2009+\u2009and CD8\u2009+\u2009T cells in melanoma patients. Mol Ther 20:1063\u20131074. https:\/\/doi.org\/10.1038\/mt.2012.11","journal-title":"Mol Ther"},{"key":"2618_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-011-1176-2","volume":"61","author":"AMT Van Nuffel","year":"2012","unstructured":"Van Nuffel AMT, Benteyn D, Wilgenhof S et al (2012) Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 61:1033\u20131043. https:\/\/doi.org\/10.1007\/s00262-011-1176-2","journal-title":"Cancer Immunol Immunother"},{"key":"2618_CR18","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824\u20131835. https:\/\/doi.org\/10.1056\/NEJMoa1709030","journal-title":"N Engl J Med"},{"key":"2618_CR19","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","volume":"34","author":"S Wilgenhof","year":"2016","unstructured":"Wilgenhof S, Corthals J, Heirman C et al (2016) Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 34:1330\u20131338. https:\/\/doi.org\/10.1200\/JCO.2015.63.4121","journal-title":"J Clin Oncol"},{"key":"2618_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00262-014-1642-8","volume":"64","author":"S Wilgenhof","year":"2015","unstructured":"Wilgenhof S, Corthals J, Van Nuffel AMT et al (2015) Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother 64:381\u2013388. https:\/\/doi.org\/10.1007\/s00262-014-1642-8","journal-title":"Cancer Immunol Immunother"},{"key":"2618_CR21","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","volume":"24","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof S, Van Nuffel AMT, Benteyn D et al (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol Off J Eur Soc Med Oncol 24:2686\u20132693. https:\/\/doi.org\/10.1093\/annonc\/mdt245","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2618_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/CJI.0b013e31821dcb31","volume":"34","author":"S Wilgenhof","year":"2011","unstructured":"Wilgenhof S, Van Nuffel AMT, Corthals J et al (2011) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34:448\u2013456. https:\/\/doi.org\/10.1097\/CJI.0b013e31821dcb31","journal-title":"J Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02618-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T19:17:20Z","timestamp":1624648640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02618-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2618"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02618-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"28 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yanina Jansen received travel grant support from BMS, MSD, Pfizer. Vibeke Kruse provided consultation, attended advisory boards, and\/or provided lectures for: Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Amgen and Sanofi. My institution received honoraria for my contribution. Jurgen Corthals has no conflict of interest. Kelly Schats: KS is an employee of HistoGeneX NV which performs immunohistochemical and molecular testing for pharmaceutical companies as part of (pre-) clinical studies that evaluate new anticancer drugs. There is no other relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Pieter-Jan Van Dam4: PJ Van Dam is an employee of HistoGeneX NV which performs immunohistochemical and molecular testing for pharmaceutical companies as part of (pre-) clinical studies that evaluate new anticancer drugs. There is no other relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Teofila Seremet received congresses and advisory fees from Novartis and one preceptorship MSD. Carlo Heirman: CH is an inventor on patents related to TriMix and is employee of eTheRNA ImmunoTherapies and may therefore have a financial interest in the development of TriMix technologies. Lieve Brochez: Advisory Board Incyte 6\/2017, Value-based health care project sponsored by Amgen. Mark Kockx: Mark Kockx is the CEO of HistoGeneX NV which performs immunohistochemical and molecular testing for pharmaceutical companies as part of (pre-) clinical studies that evaluate new anticancer drugs. There is no other relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Kris Thielemans: KT is an inventor on patents related to TriMix and DC technology and is consultant for eTheRNA ImmunoTherapies and may therefore has a financial interest in the development of TriMix technologies. Bart Neyns: Honoraria-Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche. Consulting or Advisory Role-Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche. Speakers\u2019 Bureau-Novartis. Travel, Accommodations, Expenses-Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This trial was approved by the Institutional Ethics Committee of the UZ Brussel (ClinicalTrials.gov identifier: NCT01676779). All patients provided signed informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}